nuvasive inc (NUVA) Key Developments
NuVasive, Inc. Appoints Carol Cox as Executive Vice President of Strategy and Corporate Communications
Jul 7 14
NuVasive, Inc. announced that Carol Cox has joined the company as executive vice president of Strategy and Corporate Communications effective immediately. She will report directly to Alex Lukianov, Chairman and Chief Executive Officer of NuVasive, and will join the company's Executive Committee. In this newly created role, Cox will be responsible for leading NuVasive's short- and long-term business strategies, as well as creating and managing a centralized communications function to ensure global alignment of messaging and leveraging of assets across the key areas of corporate communications, investor relations and public affairs. Included in Cox's responsibilities will also be overseeing NuVasive corporate philanthropic and cultural efforts. Cox is an executive with extensive global healthcare experience in corporate strategy, investor relations, corporate communications, media relations, brand strategy and government relations. She joins NuVasive from Sanford-Burnham Medical Research Institute (Sanford-Burnham) where she served as senior vice president, External Affairs, leading external and internal communications, philanthropy, marketing, government relations and efforts to elevate the Institute's global recognition.
NuVasive, Inc. Announces the Release of the Next Generation Monitoring Platform for Spine Surgery
Jun 23 14
NuVasive, Inc. announced the release of a next generation monitoring platform with computer-assisted surgery applications to enhance both speed and efficiency. Core to the NuVasive philosophy of facilitating reproducible outcomes in spine surgery is the procedural integration of neurophysiology and computer-assisted surgery technologies. The recently released NVM5 V2.0 hosts a comprehensive set of intraoperative technologies specifically designed for spine surgery, including the sensory monitoring modality (SSEP) for multimodality monitoring of the spinal cord and peripheral nerves, as well as refinements to the recently launched spinal rod-bending technology called Bendini. NVM5 V2.0 leverages the experience that NuVasive has accumulated through the past 12 years, with more than 250,000 spine surgeries utilizing the Company's proprietary monitoring platform. Capabilities of the NVM5 platform in spine surgery include: Nerve avoidance during an XLIF procedure in order to navigate the psoas; Nerve proximity information during pedicle cannulation and screw placement; Computer-assisted, rod-bending technology; Nerve root monitoring; Spinal cord monitoring; and Peripheral sensory nerve monitoring.
NuVasive, Inc. Approves and Adopted an Amendment to the Restated Bylaws
May 19 14
On May 13, 2014, the Board of NuVasive, Inc. pursuant to Article IX (amendments) of the company’s restated bylaws (the restated bylaws) (which generally allows the board to amend the restated bylaws by the affirmative vote of a majority of the board) approved and adopted an amendment to the restated bylaws in connection with the approval and adoption of the new form of indemnity agreement to be entered into with each of the current directors and certain current executives of the company. That amendment to the restated bylaws redefined the term 'Expenses', as contained in article VII (indemnification) therein, to exclude any amounts paid in settlement or judgment that are the result of a proceeding in which the company may be required to indemnify a director or executive.
NuVasive, Inc., Board Meeting, May 14, 2014
May 19 14
NuVasive, Inc., Board Meeting, May 14, 2014. Agenda: To consider the amendment was made to the restated bylaws.
NuVasive, Inc. - Shareholder/Analyst Call
May 8 14
Annual Shareholder Meeting